FAQ on Calidi Biotherapeutics Inc.'s Leadership Change and Clinical Growth

Who has been appointed as the new CEO of Calidi Biotherapeutics Inc.?

Eric Poma, Ph.D., has been appointed as the new Chief Executive Officer of Calidi Biotherapeutics Inc., effective April 22.

What experience does Eric Poma bring to Calidi Biotherapeutics Inc.?

Eric Poma brings over 30 years of biotech leadership experience, including significant roles at Molecular Templates where he raised over $250 million and secured strategic partnerships with major pharmaceutical companies.

What is Calidi Biotherapeutics Inc.’s focus under its new CEO?

Under its new CEO, Calidi Biotherapeutics Inc. focuses on advancing its systemic virotherapy platform and preparing for a dose-escalation trial of CLD-201 in solid tumors.

What is Calidi Biotherapeutics Inc.’s proprietary technology?

Calidi Biotherapeutics Inc. specializes in proprietary stem cell-based platforms that utilize allogeneic stem cells to carry payloads of oncolytic viruses for treating various oncology indications.

Where is Calidi Biotherapeutics Inc. headquartered?

Calidi Biotherapeutics Inc. is headquartered in San Diego, California.

How can I find more information about Calidi Biotherapeutics Inc.?

For more information, please visit www.calidibio.com or check the company’s newsroom at https://ibn.fm/CLDI.

What are the implications of Eric Poma’s appointment for Calidi Biotherapeutics Inc.?

Eric Poma’s appointment is expected to support Calidi Biotherapeutics Inc.’s transition into later-stage clinical development, leveraging his extensive experience in biotech leadership and fundraising.

What is the significance of Calidi Biotherapeutics Inc.’s clinical stage platforms?

Calidi Biotherapeutics Inc.’s clinical stage platforms are designed to protect, amplify, and potentiate oncolytic viruses, leading to enhanced efficacy and improved patient safety in treating cancer.